Post-traumatic stress disorder.
Conditions
Sponsors
TNO
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - aged between 18 and 65 years; - a primary diagnosis of PTSD according to DSM-V; - a score of > 20 on the Post-traumatic Symptom Scale at screening. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - other relevant treatment for PTSD within 3 months before start of the study; - start of new medication within 3 months before start of study; - life-time psychosis; - acute suicide risk; - current state of asthma or COPD, which necessitates medication use; - cardiovascular diseases or irregular heartbeat; - hypotension or hypertension; - pregnancy or breastfeeding; - epilepsy; - any medication contra-indicative of the use of propranolol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Present study will test whether disrupting reconsolidation by the noradrenergic beta-blocker propranolol provides long-term relief of PTSD symptoms in traumatized healthcare workers.;Secondary Objective: Not applicable.;Primary end point(s): Percent change in PTSD diagnosis and the decrease in frequency and severity of PTSD symptoms.;Timepoint(s) of evaluation of this end point: From baseline to post-treatment and 3-months follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Not applicable.;Timepoint(s) of evaluation of this end point: Not applicable. | — |
Countries
Netherlands
Contacts
Public ContactClinical Trial Information Desk
TNO
Outcome results
None listed